CBG oil is a product that is obtained from the cannabis plant. Chemically, CBG oil is made up of over 400 different compounds. By weight, 10% of minutely dispersed particles in CBG oil are cannabinoids. There has been a lot of research done on the effects of CBG oil and although there have not been enough studies conducted to meet clinical standards for prescription of this oil, anecdotal evidence continues to show positive results in alleviating psychological conditions such as anxiety disorder and depression.
Because it is derived from hemp plants (a variety of Cannabis Sativa), CBG oil does not produce psychoactive effects like its other extracts; thus, making it legal in most regions where marijuana possession isn’t permitted by law (please check your local laws before purchasing).
CBG oils is different from CBD oil
Cannabigerol, or CBG for short, is one of the 104 chemical compounds found in cannabis. Like THC and CBD, it’s a cannabinoid – a unique type of chemical compound that interacts with the body’s endocannabinoid system (the endogenous neurotransmitter system that manages homeostasis).
Despite CBG’s prevalence throughout various strains of marijuana, until recently very little research has been done on how it affects the human body. In recent years however, as increasing amounts of scientific data on cannabinoids has become available and more countries decriminalized or legalized medical marijuana use (in direct opposition to international treaties), new information about this cannabinoid is starting to emerge.
How was CBG discovered?
In 1964, Israeli scientist Raphael Mechoulam was able to isolate and name CBG – but even then, the total cannabinoid content of cannabis sativa was still a mystery. In fact, not too long after Mechoulam’s discovery that same year, a young scientist named Francis Mechner published a paper entitled “The Botany of Cannabis Sativa” in which he claimed the most abundant compound found in marijuana is THC.
In 1984, as new methods for cannabinoid extraction were being developed, researchers discovered that some cannabinoids fall into more than one category. In particular, they found that CBD actually has a very low affinity for CB1 and CB2 receptors – meaning it doesn’t stimulate them as strongly as other cannabinoids do. This new information about chemistry led Dr. Geoffrey Guy and Dr. Brian Whittle to start studying non-psychoactive cannabinoids in more detail, with CBG being one of the first they focused on.